This phase 1b trial studies the biologic effect of 9cUAB30 on early stage breast cancer. 9cUAB30 is a retinoid X receptor (RXR)-selective retinoid that acts in a tissue selective manner with the goal of minimizing side effects, a necessary feature of agents under development for cancer prevention.
|Effective start/end date||5/10/21 → 2/28/22|
- University of Wisconsin-Madison (Agmt 0000001301//Task Order HHSN26100009)
- National Cancer Institute (Agmt 0000001301//Task Order HHSN26100009)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.